This session will be live streamed in the conference room. Erik will be available for live virtual Q&A later in the morning

• How do investors see the next 5-10 years?
• Trends in technologies and modalities – what’s on the horizon?
• What are investors looking for in investee companies?
• How can we drive more collaboration between investment community and big pharma to drive better outcomes? Can pharma advise on substrate they are investing in?
• How can companies position themselves for capital success?
• What sort of companies are investors looking for? What should companies NOT do?

• R&D – current challenges of moving innovation/candidates forward
• VC/Pharma – what do they look for in assets and what motivates them to license? What are they looking for in a partner?
• What are Australia’s capabilities in closing the bench to bed gap
  • How biotechs can ensure asset fits with what partners are looking for
  • Finding your hook – establishing superiority to what is currently avilable or the standard of care
  • What is your indication worth?
  • Key messages and tips e.g. how to ensure more commercialization potential for your asset

• Vouchers, tools, skills and advice
• Accessing government funding – what is it for and how can companies access it?
• Understanding how to leverage different schemes and incentives effectively

• How do we get patients through the door?
• Considering the whole process of patient recruitment from finding patients, to contacting etc
• Recruitment in healthy volunteers
• Ensuring diversity – understanding the FDA guidance and why it’s important
• Telehealth and teletrials – who are they suited to and the impact on recruitment
• Decentralised clinical trials – does it create more opportunities, accelerate recruitment and save costs?
• Machine learning to de risk and predictive analysis to apply targeted recruitment/retention plans
• Ensuring predictability

• Understanding the perils of getting it wrong and what it takes to get it right
• Understanding the global view on translation and the challenges
• The different translation models, how we measure and execute:
  • University to industry translation
  • Industry knowledge translating through to university – encouraging greater agility
  • Industry to industry translation
• What does the recent Australian Government University Research Commercialisation Action Plan and the BTF mean for universities and industry? What impact will it have?
• What are the opportunities for biotechs and industry here?
• How is translation giving rise to non-traditional companies being more engaged in the sector? What are the opportunities for partnering on strategy?

• Changes in pharma transport and logistics – the impact of the pandemic
• Cost of transport
• Predictive modelling around the cost of cold chain
• The impacts on pricing strategy

• To CEO or not to CEO?
• Putting together a clinical or scientific advisory board – where do you start
• Acquisition – how do you make that decision?
• Raising equity
• Regulation and reimbursement
• Making the leap into global markets – where to start and how to get it right
• Top 5 things which went wrong and learnings to share